XBiotech (XBIT) Competitors

XBiotech (NASDAQ:XBIT) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Does the media prefer XBIT or ARCT?

In the previous week, Arcturus Therapeutics had 9 more articles in the media than XBiotech. MarketBeat recorded 10 mentions for Arcturus Therapeutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.87 beat Arcturus Therapeutics' score of 1.47 indicating that XBiotech is being referred to more favorably in the media.

Company	Overall Sentiment
XBiotech	Very Positive
Arcturus Therapeutics	Positive

Do analysts recommend XBIT or ARCT?

Arcturus Therapeutics has a consensus price target of $53.50, suggesting a potential upside of 322.92%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcturus Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arcturus Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11

Does the MarketBeat Community favor XBIT or ARCT?

Arcturus Therapeutics received 134 more outperform votes than XBiotech when rated by MarketBeat users. However, 69.82% of users gave XBiotech an outperform vote while only 66.42% of users gave Arcturus Therapeutics an outperform vote.

Company	Underperform	Outperform
XBiotech	Outperform Votes 317 69.82%	Underperform Votes 137 30.18%
Arcturus Therapeutics	Outperform Votes 451 66.42%	Underperform Votes 228 33.58%

Which has better earnings & valuation, XBIT or ARCT?

XBiotech has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	$4.01M	21.44	-$24.56M	-$1.29	-2.19
Arcturus Therapeutics	$131.27M	2.61	-$29.73M	-$2.53	-5.00

Which has more risk and volatility, XBIT or ARCT?

XBiotech has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500.

Do insiders & institutionals believe in XBIT or ARCT?

55.7% of XBiotech shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 33.1% of XBiotech shares are held by insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is XBIT or ARCT more profitable?

XBiotech has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -36.39%. XBiotech's return on equity of -15.99% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-15.99%	-14.85%
Arcturus Therapeutics	-36.39%	-22.39%	-14.81%

Summary

Arcturus Therapeutics beats XBiotech on 10 of the 19 factors compared between the two stocks.